Summary

Article Metadata

PRGN-2012 Complete Response Study

This is a news story, published by Precigen, that relates primarily to Complete Response news.

Complete Response news

For more Complete Response news, you can click here:

more Complete Response news

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

Precigen news

For more news from Precigen, you can click here:

more news from Precigen

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

Recurrent Respiratory Papillomatosis

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest RRP surgeries news, Clinical Efficacy Summary news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

Precigen

Precigen

•

Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response | Precigen

Precigen

Summary

Nutrition label

86% Informative

PRGN-2012 has the potential to be the first FDA -approved therapeutic for the treatment of RRP .

RRP is a rare, devastating HPV -mediated chronic disease characterized by growth of benign tumors for which the current standard-of-care is repeated surgeries.

The Phase 1/2 study enrolled a total of 38 patients.

Quality of life, as evaluated using the validated VHI-10, improved from a mean of 25 (range: 12 -38) at baseline to 7 at 24 weeks post PRGN-2012 treatment in patients with Complete Response .

No surgeries needed during 12 months post-treatment compared to 12 months pre-treatment.

VR Score

92

Informative language

93

Neutral language

52

Article tone

formal

Language

English

Language complexity

44

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

long-living

External references

20

https://c212.net/c/link/?t=0&l=en&o=4180831-1&h=3385772750&u=https%3A%2F%2Finvestors.precigen.com%2Fevents%2Fevent-details%2Fwebcast-pivotal-study-results-prgn-2012-recurrent-respiratory-papillomatosis&a=webcast+event+today+at+6%3A00+PM+CT+%2F+7%3A00+PM+ET https://c212.net/c/link/?t=0&l=en&o=4180831-1&h=3670277215&u=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT04432597%3Fterm%3DPRGN-2009%26draw%3D2%26rank%3D1&a=NCT04432597 https://c212.net/c/link/?t=0&l=en&o=4180831-1&h=3644036594&u=https%3A%2F%2Ftwitter.com%2Fprecigen&a=%40Precigen https://c212.net/c/link/?t=0&l=en&o=4180831-1&h=1884765569&u=https%3A%2F%2Fwww.youtube.com%2Fchannel%2FUCbd51C9ftUDEnSfbheMjF2Q&a=YouTube https://c212.net/c/link/?t=0&l=en&o=4180831-1&h=1780789710&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fprecigen%2F&a=LinkedIn https://c212.net/c/link/?t=0&l=en&o=4180831-1&h=2639245113&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3410411-1%26h%3D1106264887%26u%3Dhttps%253A%252F%252Finvestors.precigen.com%252Fnews-releases%252Fnews-release-details%252Fprecigen-receives-fda-orphan-drug-designation-prgn-2012%26a%3DOrphan%2BDrug%2BDesignation&a=Orphan+Drug+Designation https://mma.prnewswire.com/media/2427813/precigen.html https://c212.net/c/link/?t=0&l=en&o=4180831-1&h=1179929741&u=http%3A%2F%2Fwww.precigen.com%2F&a=www.precigen.com https://c212.net/c/link/?t=0&l=en&o=4180831-1&h=3191025001&u=https%3A%2F%2Finvestors.precigen.com%2Fnews-releases%2Fnews-release-details%2Fprecigen-announces-fda-confirmation-ongoing-phase-12-study-prgn&a=an+accelerated+approval+pathway+for+RRP+from+the+US+Food+and+Drug+Administration+(FDA https://www.prnewswire.com/news-releases/precigen-announces-groundbreaking-pivotal-study-data-for-prgn-2012-in-patients-with-recurrent-respiratory-papillomatosis-in-which-more-than-half-of-patients-achieved-complete-response-302161493.html https://c212.net/c/link/?t=0&l=en&o=4180831-1&h=2083953313&u=https%3A%2F%2Finvestors.precigen.com%2Fnews-releases%2Fnews-release-details%2Fprecigen-receives-breakthrough-therapy-designation-prgn-2012&a=Breakthrough+Therapy+Designation https://c212.net/c/link/?t=0&l=en&o=4180831-1&h=3089498317&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4164300-1%26h%3D620433082%26u%3Dhttps%253A%252F%252Fwww.science.org%252Fdoi%252Ffull%252F10.1126%252Fscitranslmed.adj0740%26a%3DScience%2BTranslational%2BMedicine&a=Science+Translational+Medicine https://c212.net/c/link/?t=0&l=en&o=4180831-1&h=2835321009&u=https%3A%2F%2Finvestors.precigen.com%2Fnews-releases%2Fnews-release-details%2Fprecigen-receives-orphan-drug-designation-prgn-2012-treatment&a=from+the+European+Commission https://c212.net/c/link/?t=0&l=en&o=4180831-1&h=4248929834&u=https%3A%2F%2Finvestors.precigen.com%2Fnews-releases%2Fnews-release-details%2Fprecigen-receives-orphan-drug-designation-prgn-2012-treatment&a=Orphan+Drug+Designation https://mma.prnewswire.com/media/694013/Precigen_Logo.html https://c212.net/c/link/?t=0&l=en&o=4180831-1&h=339630427&u=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06157151%3Fterm%3Dprgn-2009%26rank%3D2&a=NCT06157151 https://c212.net/c/link/?t=0&l=en&o=4180831-1&h=216765067&u=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05996523%3Fterm%3DNCT05996523%26rank%3D1&a=NCT05996523 https://c212.net/c/link/?t=0&l=en&o=4180831-1&h=3444601712&u=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT04724980%3Fterm%3DPRGN-2012%26draw%3D2%26rank%3D1&a=NCT04724980 https://c212.net/c/link/?t=0&l=en&o=4180831-1&h=227381745&u=https%3A%2F%2Fprecigen.com%2F&a=Precigen%2C+Inc.https://c212.net/c/link/?t=0&l=en&o=4180831-1&h=193932610&u=https%3A%2F%2Finvestors.precigen.com%2Fnews-releases%2Fnews-release-details%2Fprecigen-receives-fda-orphan-drug-designation-prgn-2012&a=Orphan+Drug+Designation+from+the+FDA

Source diversity

3

c212.net mma.prnewswire.com www.prnewswire.com

Affiliate links

no affiliate links

Read full article